Letters/Replies
Suvorexant for Preventing Alzheimer's Disease
Tomoyuki Kawada MD,
Corresponding Author
Tomoyuki Kawada MD
Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan
Address correspondence to Dr Kawada, Department of Hygiene and Public Health, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo 113-8602, Japan. E-mail: [email protected]
Search for more papers by this author
Tomoyuki Kawada MD,
Corresponding Author
Tomoyuki Kawada MD
Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan
Address correspondence to Dr Kawada, Department of Hygiene and Public Health, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo 113-8602, Japan. E-mail: [email protected]
Search for more papers by this author
First published: 27 June 2023
No abstract is available for this article.
References
- 1Lucey BP, Liu H, Toedebusch CD, et al. Suvorexant acutely decreases tau phosphorylation and Aβ in the human CNS. Ann Neurol 2023; 94:27–40.
- 2Gao F, Liu T, Tuo M, Chi S. The role of orexin in Alzheimer disease: from sleep-wake disturbance to therapeutic target. Neurosci Lett 2021; 765:136247.
- 3Liguori C. Orexin and Alzheimer's disease. Curr Top Behav Neurosci 2017; 33: 305–322.
- 4Krystal AD. New developments in insomnia medications of relevance to mental health disorders. Psychiatr Clin North Am 2015; 38: 843–860.
